AstraZeneca: IMFINZI (durvalumab) plus chemotherapy further

HIMALAYA Phase III trial exploratory results support the benefit of tremelimumab added to IMFINZI in unresectable liver cancer regardless of etiology Updated results from the TOPAZ-1 Phase III trial

Related Keywords

Paris , France General , France , China , Seoul , Soult Ukpyolsi , South Korea , Japan , United States , Thailand , India , United Kingdom , Cambridge , Cambridgeshire , Canada , America , Jessica Mcduell , South East Asia , Daiichi Sankyo , Brendan Mcevoy , Gastroenterol Hepatol , Susan Galbraith , Company Immuno , National Comprehensive Cancer Network Inc , Seoul National University College Of Medicine , Merck Co Inc , Company On Twitter Astrazeneca , Astrazeneca , Division Of Medical Oncology , European Society For Medical Oncology , European Society , Medical Oncology , Internal Medicine , Seoul National University Hospital , Seoul National University College , Executive Vice President , Response Evaluation Criteria In Solid Tumors , Thyroid Disorders , Hyperthyroidism Immune Mediated , Immune Mediated Nephritis , Immune Mediated Dermatology , Stevens Johnson Syndrome , Prescribing Information , South America , Rare Diseases , Renal Metabolism , Aliment Pharmacol , Biliary Tract , Accessed September , Tailored Oncology Treatment , Gastroenterol Res , Practice Guidelines , Comprehensive Cancer Network , Rev Gastroenterol , Imfinzi , Durvalumab , Plus , Chemotherapy , Urther , Mproved , Verall , Survival , Benefit , Dvanced , Miliary , Tract , Dancer , Topaz , Hase , Trial , Educing , Risk , Death , Dditional , Follow ,